{"id":"hepsera-and-lamivudine","safety":{"commonSideEffects":[{"rate":null,"effect":"Nephrotoxicity (renal dysfunction)"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Asthenia/fatigue"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Lactic acidosis"}]},"_chembl":{"chemblId":"CHEMBL141","moleculeType":"Small molecule","molecularWeight":"229.26"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Both drugs are nucleoside/nucleotide analogs that inhibit hepatitis B virus (HBV) reverse transcriptase, preventing viral DNA synthesis and replication. Adefovir is a nucleotide analog with activity against both wild-type and lamivudine-resistant HBV, while lamivudine is a nucleoside analog. When used in combination, they provide complementary antiviral activity and reduce the risk of resistance development.","oneSentence":"Hepsera (adefovir dipivoxil) and lamivudine are nucleoside/nucleotide reverse transcriptase inhibitors that block viral replication in hepatitis B by inhibiting the reverse transcriptase enzyme.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:47:33.013Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis B infection"},{"name":"Hepatitis B with lamivudine-resistant virus"}]},"trialDetails":[{"nctId":"NCT00059267","phase":"","title":"Prevention of Recurrent Hepatitis B After Liver Transplantation","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2001-03","conditions":"Hepatitis B, Cirrhosis, Acute Liver Failure","enrollment":317},{"nctId":"NCT03736265","phase":"NA","title":"Carvedilol for Prevention of Esophageal Varices Progression","status":"UNKNOWN","sponsor":"Beijing Friendship Hospital","startDate":"2017-10-09","conditions":"Cirrhosis, Liver, Portal Hypertension","enrollment":240},{"nctId":"NCT00307242","phase":"PHASE4","title":"Study Comparing the Safety of Switching From Lamivudine to Adefovir Dipivoxil Versus Overlapping Lamivudine and Adefovir Before Adefovir Dipivoxil Monotherapy in Patients With Chronic Hepatitis B","status":"COMPLETED","sponsor":"Thomas Jefferson University","startDate":"2005-06-17","conditions":"Chronic Hepatitis B","enrollment":40},{"nctId":"NCT00033163","phase":"PHASE2","title":"A Comparison of Adefovir and Tenofovir for the Treatment of Lamivudine-Resistant Hepatitis B Virus in People With HIV","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections, Hepatitis B","enrollment":90},{"nctId":"NCT00001087","phase":"PHASE2","title":"The Effectiveness of Nelfinavir and Efavirenz, Used Alone or Together, Combined With Other Anti-HIV Drugs in Patients Who Have Taken Anti-HIV Drugs","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":300},{"nctId":"NCT00000885","phase":"PHASE2","title":"Treatment Success and Failure in HIV-Infected Subjects Receiving Indinavir in Combination With Nucleoside Analogs: A Rollover Study for ACTG 320","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":440},{"nctId":"NCT05021406","phase":"NA","title":"Extension Study of Carvedilol RCT Study","status":"UNKNOWN","sponsor":"Beijing Friendship Hospital","startDate":"2021-01-08","conditions":"Liver Cirrhosis, Portal Hypertension","enrollment":240},{"nctId":"NCT03491553","phase":"PHASE2","title":"Safety, Tolerability and Antiviral Activity of Selgantolimod in Virally-Suppressed Participants With Chronic Hepatitis B","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2018-04-06","conditions":"Chronic Hepatitis B","enrollment":48},{"nctId":"NCT01353742","phase":"PHASE1","title":"Lamivudine and Adefovir Dipivoxil Fixed Dose Combination","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-02-21","conditions":"Hepatitis B, Chronic","enrollment":40},{"nctId":"NCT00455091","phase":"","title":"A Phase III Study in Post-operative HBV-related Hepatocellular Carcinoma","status":"TERMINATED","sponsor":"National Health Research Institutes, Taiwan","startDate":"2007-05","conditions":"Hepatocellular Carcinoma","enrollment":117},{"nctId":"NCT01732367","phase":"PHASE4","title":"TDF VS LAM + ADV in LAM + ADV Treated LAM-resistant CHB Patients With Undetectable Hepatitis B Virus DNA","status":"COMPLETED","sponsor":"Keimyung University Dongsan Medical Center","startDate":"2012-11","conditions":"Chronic Hepatitis B","enrollment":171},{"nctId":"NCT00023309","phase":"PHASE2","title":"Lamivudine and Adefovir to Treat Chronic Hepatitis B","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2001-08","conditions":"HBV (Hepatitis B Virus), Hepatitis B, Hepatitis","enrollment":41},{"nctId":"NCT01491295","phase":"PHASE4","title":"Switch to Tenofovir Versus Continue Lamivudine/Adefovir Treatment in Lamivudine-resistance Chronic Hepatitis B Patients","status":"UNKNOWN","sponsor":"Taipei Veterans General Hospital, Taiwan","startDate":"2012-09","conditions":"Chronic Hepatitis B","enrollment":160},{"nctId":"NCT02598063","phase":"PHASE4","title":"A Study to Evaluate Efficacy and Safety of Peginterferon Alfa-2a (Pegasys) and Adeforvir Dipivoxil (ADV) in Participants With Lamivudine-Resistant Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2005-10","conditions":"Hepatitis B, Chronic","enrollment":255},{"nctId":"NCT02560649","phase":"PHASE4","title":"An Exploratory Study of RGT Strategy on Optimal NUC-experienced Patients","status":"UNKNOWN","sponsor":"Ruijin Hospital","startDate":"2015-05","conditions":"Chronic Hepatitis B","enrollment":324},{"nctId":"NCT00986778","phase":"PHASE4","title":"Entecavir Plus Adefovir in Lamivudine-Resistant Patients","status":"WITHDRAWN","sponsor":"Bristol-Myers Squibb","startDate":"2009-12","conditions":"Hepatitis B, Chronic","enrollment":""},{"nctId":"NCT01720238","phase":"","title":"Clinical Effects and Cost-effectiveness Analysis of Early Anti-viral Therapy on HBV-related Compensated Liver Cirrhosis","status":"UNKNOWN","sponsor":"Beijing Friendship Hospital","startDate":"2012-03","conditions":"Liver Cirrhosis, Hepatitis B","enrollment":621},{"nctId":"NCT01023217","phase":"PHASE4","title":"Entecavir Plus Adefovir in Lamivudine-Resistant Chronic Hepatitis B Patients Who Fail Lamivudine Plus Adefovir","status":"COMPLETED","sponsor":"Asan Medical Center","startDate":"2009-11","conditions":"Hepatitis B, Chronic","enrollment":90},{"nctId":"NCT01597934","phase":"PHASE4","title":"Antiviral Efficacy of Switching to ETV Plus TDF","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2012-08","conditions":"Chronic Hepatitis B","enrollment":104},{"nctId":"NCT00410202","phase":"PHASE3","title":"Entecavir Plus Adefovir Combination Therapy Versus Entecavir Monotherapy vs Therapy With Adefovir Plus Lamivudine for Chronic Hepatitis B Infected Subjects With Lamivudine-resistant Virus","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2008-03","conditions":"Hepatitis B, Chronic","enrollment":629},{"nctId":"NCT01844063","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of Diverse Mesenchymal Stem Cells Transplantation for Liver Failure","status":"UNKNOWN","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2013-07","conditions":"Liver Failure","enrollment":210},{"nctId":"NCT01804387","phase":"PHASE4","title":"Comparison of Telbivudine Plus Adefovir With Lamivudine Plus Adefovir for the Treatment of Lamivudine-resistant Chronic Hepatitis B at 52 Weeks: A Pilot Study","status":"UNKNOWN","sponsor":"Korea University","startDate":"2011-05","conditions":"Chronic Hepatitis B","enrollment":60},{"nctId":"NCT01718587","phase":"PHASE1, PHASE2","title":"Difference in Efficacy Between Stem Cell Transplantation and Classical Therapy in Liver Cirrhosis Patients","status":"UNKNOWN","sponsor":"General Hospital of Chinese Armed Police Forces","startDate":"2012-11","conditions":"Liver Cirrhosis","enrollment":60},{"nctId":"NCT00531167","phase":"PHASE4","title":"Adding Adefovir Dipivoxil Versus Switching to Entecavir in Patients With Lamivudine-resistant Chronic Hepatitis B","status":"COMPLETED","sponsor":"Korea University","startDate":"2007-04","conditions":"Chronic Hepatitis B","enrollment":219},{"nctId":"NCT00095121","phase":"PHASE3","title":"Safety and Efficacy of Adefovir Dipivoxil in Children and Adolescents With Chronic Hepatitis B","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2004-06","conditions":"Chronic Hepatitis B","enrollment":173},{"nctId":"NCT00376259","phase":"PHASE3","title":"Study of Combination Therapy With LdT Plus Adefovir Versus Adefovir Alone","status":"TERMINATED","sponsor":"Novartis","startDate":"2007-01","conditions":"Hepatitis B","enrollment":43},{"nctId":"NCT00798460","phase":"PHASE4","title":"Efficacy of Clevudine Plus Lamivudine for Lamivudine-resistant Chronic Hepatitis B Patients","status":"TERMINATED","sponsor":"Inje University","startDate":"2008-12","conditions":"Chronic Hepatitis B","enrollment":30},{"nctId":"NCT00489151","phase":"NA","title":"A Randomized Study Comparing Lamivudine Versus Adefovir Dipivoxil for Prevention of zHBV Reactivation in HBsAg Seropositive Patients Undergoing Cytotoxic Chemotherapy","status":"UNKNOWN","sponsor":"Hospital Authority, Hong Kong","startDate":"2005-06","conditions":"Hepatitis B","enrollment":70},{"nctId":"NCT00316719","phase":"PHASE3","title":"Adefovir Dipivoxil In Compensated Chronic Hepatitis B Patients","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-01","conditions":"Chronic Hepatitis B","enrollment":105},{"nctId":"NCT00895596","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Study of LB80380 in the Patients With Lamivudine-Refractory Chronic Hepatitis B","status":"COMPLETED","sponsor":"LG Life Sciences","startDate":"2004-03","conditions":"Chronic Hepatitis B","enrollment":65},{"nctId":"NCT00810524","phase":"PHASE4","title":"Influence of Antiviral Treatment to the Long-Term Prognosis of Patients With Chronic HBV Infection","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2007-01","conditions":"Hepatitis B, Chronic","enrollment":600},{"nctId":"NCT00013702","phase":"PHASE2","title":"Adefovir Dipivoxil to Treat Hepatitis B in HIV-Infected Patients","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2001-03","conditions":"Hepatitis B, HIV Infection","enrollment":30},{"nctId":"NCT00023153","phase":"PHASE3","title":"Lamivudine and Adefovir to Treat Chronic Hepatitis B Infection in People With and Without HIV Infection","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2001-08","conditions":"HIV Infections, Chronic Hepatitis B","enrollment":100},{"nctId":"NCT00230477","phase":"PHASE4","title":"Hepsera Versus Hepsera Plus Lamivudine for Treatment of Chronic Hepatitis B in Patients With Normal ALT","status":"COMPLETED","sponsor":"University of Washington","startDate":"2003-04","conditions":"Hepatitis B","enrollment":19},{"nctId":"NCT00002234","phase":"PHASE2","title":"Safety and Effectiveness of Giving an Anti-HIV Drug Combination of Adefovir Dipivoxil Plus Didanosine Plus Efavirenz Plus Lamivudine Once Daily to HIV-Infected Patients","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"","conditions":"HIV Infections","enrollment":25},{"nctId":"NCT00002379","phase":"PHASE2","title":"The Safety and Effectiveness of Adefovir Dipivoxil Plus Indinavir Combined With Zidovudine or Lamivudine or Stavudine in HIV-Infected Patients Who Have Not Taken Anti-HIV Drugs","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"","conditions":"HIV Infections","enrollment":100},{"nctId":"NCT00002184","phase":"PHASE2","title":"A Phase II, Stratified, Randomized, Double-Blind, Multi-Center Study of the Safety and Efficacy of Adefovir Dipivoxil (ADF) at Two Dose Levels in Triple Combination Therapies With Protease Inhibitors (PI) and Nucleoside Reverse Transcriptase Inhibitors (RTI) for the Treatment of HIV-Infected Patient","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"","conditions":"HIV Infections","enrollment":120}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Hepsera and lamivudine","genericName":"Hepsera and lamivudine","companyName":"University of Washington","companyId":"university-of-washington","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Hepsera (adefovir dipivoxil) and lamivudine are nucleoside/nucleotide reverse transcriptase inhibitors that block viral replication in hepatitis B by inhibiting the reverse transcriptase enzyme. Used for Chronic hepatitis B infection, Hepatitis B with lamivudine-resistant virus.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}